Trader consensus on Polymarket overwhelmingly prices a Kailera Therapeutics (KLRA) IPO closing market cap exceeding $2.1 billion at 99.4% implied probability, reflecting robust demand for the clinical-stage biotech's obesity-focused GLP-1 agonist pipeline amid surging sector enthusiasm. The company priced its upsized initial public offering at the $16 high-end of its $14–$16 range late April 16, raising a record-breaking $625 million across 39.1 million shares—the largest biotech IPO since Moderna's 2018 debut—bolstered by backing from Chinese parent Hengrui Pharmaceuticals and phase 3 trial momentum. Shares debuted strongly at $26 on Nasdaq April 17, implying a post-IPO market cap above $3 billion on ~118 million shares outstanding, with early trading volume underscoring investor conviction. Realistic challenges include late-session profit-taking or broader biotech volatility, though momentum in GLP-1 therapeutics limits downside risk.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日2.1B+ 99.4%
1.8B–1.9B <1%
2.0B–2.1B <1%
1.9B–2.0B <1%
$26,612 Vol.
$26,612 Vol.
2026/04/17
1.8B–1.9B
1%
1.9B–2.0B
<1%
2.0B–2.1B
1%
2.1B+
99%
2.1B+ 99.4%
1.8B–1.9B <1%
2.0B–2.1B <1%
1.9B–2.0B <1%
$26,612 Vol.
$26,612 Vol.
2026/04/17
1.8B–1.9B
$2,327 Vol.
1%
1.9B–2.0B
$2,633 Vol.
<1%
2.0B–2.1B
$2,939 Vol.
1%
2.1B+
$13,205 Vol.
99%
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader consensus on Polymarket overwhelmingly prices a Kailera Therapeutics (KLRA) IPO closing market cap exceeding $2.1 billion at 99.4% implied probability, reflecting robust demand for the clinical-stage biotech's obesity-focused GLP-1 agonist pipeline amid surging sector enthusiasm. The company priced its upsized initial public offering at the $16 high-end of its $14–$16 range late April 16, raising a record-breaking $625 million across 39.1 million shares—the largest biotech IPO since Moderna's 2018 debut—bolstered by backing from Chinese parent Hengrui Pharmaceuticals and phase 3 trial momentum. Shares debuted strongly at $26 on Nasdaq April 17, implying a post-IPO market cap above $3 billion on ~118 million shares outstanding, with early trading volume underscoring investor conviction. Realistic challenges include late-session profit-taking or broader biotech volatility, though momentum in GLP-1 therapeutics limits downside risk.
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
マーケット開始日： Apr 14, 2026, 5:05 PM ET
音量
$26,612終了日
2026/04/17マーケット開始日
Apr 14, 2026, 5:05 PM ETResolver
0x69c47De9D...This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader consensus on Polymarket overwhelmingly prices a Kailera Therapeutics (KLRA) IPO closing market cap exceeding $2.1 billion at 99.4% implied probability, reflecting robust demand for the clinical-stage biotech's obesity-focused GLP-1 agonist pipeline amid surging sector enthusiasm. The company priced its upsized initial public offering at the $16 high-end of its $14–$16 range late April 16, raising a record-breaking $625 million across 39.1 million shares—the largest biotech IPO since Moderna's 2018 debut—bolstered by backing from Chinese parent Hengrui Pharmaceuticals and phase 3 trial momentum. Shares debuted strongly at $26 on Nasdaq April 17, implying a post-IPO market cap above $3 billion on ~118 million shares outstanding, with early trading volume underscoring investor conviction. Realistic challenges include late-session profit-taking or broader biotech volatility, though momentum in GLP-1 therapeutics limits downside risk.
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
音量
$26,612終了日
2026/04/17マーケット開始日
Apr 14, 2026, 5:05 PM ETResolver
0x69c47De9D...Trader consensus on Polymarket overwhelmingly prices a Kailera Therapeutics (KLRA) IPO closing market cap exceeding $2.1 billion at 99.4% implied probability, reflecting robust demand for the clinical-stage biotech's obesity-focused GLP-1 agonist pipeline amid surging sector enthusiasm. The company priced its upsized initial public offering at the $16 high-end of its $14–$16 range late April 16, raising a record-breaking $625 million across 39.1 million shares—the largest biotech IPO since Moderna's 2018 debut—bolstered by backing from Chinese parent Hengrui Pharmaceuticals and phase 3 trial momentum. Shares debuted strongly at $26 on Nasdaq April 17, implying a post-IPO market cap above $3 billion on ~118 million shares outstanding, with early trading volume underscoring investor conviction. Realistic challenges include late-session profit-taking or broader biotech volatility, though momentum in GLP-1 therapeutics limits downside risk.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問